Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Sweden · Delayed Price · Currency is SEK | Market Cap | 114.56B |
| Revenue (ttm) | 27.85B |
| Net Income (ttm) | 13.00M |
| Shares Out | 344.66M |
| EPS (ttm) | 0.04 |
| PE Ratio | 8,812.60 |
| Forward PE | 19.52 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 68,336 |
| Average Volume | 333,555 |
| Open | 327.20 |
| Previous Close | 332.40 |
| Day's Range | 326.80 - 333.60 |
| 52-Week Range | 241.80 - 349.40 |
| Beta | 0.19 |
| RSI | 58.19 |
| Earnings Date | Feb 5, 2026 |
About STO:SOBI
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocy... [Read more]
Full Company ProfileFinancial Performance
In 2024, STO:SOBI's revenue was 26.03 billion, an increase of 17.65% compared to the previous year's 22.12 billion. Earnings were 3.89 billion, an increase of 61.27%.
Financial StatementsNews
Positioning Barbados as the Caribbean's Life Sciences Hub
BRIDGETOWN, Barbados, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Export Barbados (BIDC) and EarlyHealth Group (EHG), headquartered in Dubai, United Arab Emirates, have signed a Letter of Intent to jointly esta...
Data presented at ACR Convergence 2025 highlight Sobi's commitment to advancing care across rare and underserved inflammatory conditions
NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (e mapalumab) data showed response rates in patients with MAS in Still's disease across MAS subtypes...
Swedish Orphan Biovitrum AB (BIOVF) Q3 2025 Earnings Call Highlights: Strong Growth and ...
Swedish Orphan Biovitrum AB (BIOVF) Q3 2025 Earnings Call Highlights: Strong Growth and Strategic Advancements Amid Challenges
Q3 2025 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Q3 2025 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (SWOBY) Q3 2025 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) 2025 Q3 - Results - Earnings Call Presentation
Sobi Q3 Adj. EBITA Rises
(RTTNews) - Swedish Orphan Biovitrum AB reported a third quarter loss of 2.89 billion Swedish kronor compared to profit of 1.46 billion kronor, prior year. Loss per share was 8.32 kronor compared to p...
Sobi raises 2025 financial forecast after Q3 revenue jumps 21%
KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs
KalVista Pharma (KALV) stock and Ionis Pharma (IONS) stock are in focus as the EU approve their rare disease drugs, Ekterly and Tryngolza, respectively. Read more here.
Ionis Pharmaceuticals And Sobi Say EU Approves TRYNGOLZA For Familial Chylomicronemia Syndrome
(RTTNews) - Ionis Pharmaceuticals, Inc. (IONS) and Swedish biopharmaceutical company Sobi announced Friday that TRYNGOLZA (olezarsen) has been approved in the European Union (EU) as an adjunct to diet...
Swedish Orphan Biovitrum AB (Publ) (SWOBY) Discusses On NASP And Uncontrolled Gout Call (Transcript)
Discover how NASP, an innovative uricase therapy, offers new hope for uncontrolled gout
Swedish Orphan Biovitrum AB (publ) - Special Call
Swedish Orphan Biovitrum AB (publ) - Special Call Company Participants Guido Oelkers - CEO & President Matthew Winfield Conference Call Participants Herbert S. B. Baraf Rehan Azeem Gonzalo Artiach Cas...
10 stocks to consider if you want alternatives to the expensive S&P 500
Stocks in developed economies outside the U.S. tend to trade at lower valuations. Some of the companies are expected to expand their businesses rapidly over the next two years.
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2025 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) 2025 Q2 - Results - Earnings Call Presentation
The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2025 Q2 earnings call.
Swedish Orphan Biovitrum AB (BIOVF) Reports Strong Q2 Revenue Growth
Swedish Orphan Biovitrum AB (BIOVF) Reports Strong Q2 Revenue Growth
Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK 2.36, revenue of SEK 6.17B; reaffirms FY25 outlook
Apellis signs royalty purchase deal with Sobi for Aspaveli
Swedish Orphan Biovitrum: Haematology Focus Seems To Be Paying Off
BIOVF is moving from legacy products to a six-asset strategic portfolio that's mostly centered on Haematology. In particular, its Haematology segment contributed 71.6% of BIOVF's Q1 revenues, and five...
Swedish Orphan Biovitrum AB (BIOVF) Q1 2025 Earnings Call Transcript
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM , April 1, 2025 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be ...
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
Swedish Orphan Biovitrum targets high single-digit growth in 2025 amid robust pipeline advancements
Earnings Call Insights: Swedish Orphan Biovitrum (OTCPK:BIOVF) Q4 2024Management ViewCEO Guido Oelkers highlighted an 8% growth in Q4 revenues, driven...